Gulhati, PatSchalck, AislynJiang, ShanShang, XiaoyingWu, Chang-JiunHou, PingpingHernandez Ruiz, ShariaSolis Soto, LuisaParra, EdwinYing, HaoqiangHan, JinchengDey, PrasenjitLi, JunDeng, PingnaSei, EmiMaeda, Dean Y.Zebala, John A.Spring, Denise J.Kim, MichaelWang, HuaminMaitra, AnirbanMoore, DirkClise-Dwyer, KarenWang, Y. AlanNavin, Nicholas E.DePinho, Ronald A.2024-02-012024-02-012023Gulhati P, Schalck A, Jiang S, et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat Cancer. 2023;4(1):62-80. doi:10.1038/s43018-022-00500-zhttps://hdl.handle.net/1805/38273Pancreatic ductal adenocarcinoma (PDAC) is considered non-immunogenic, with trials showing its recalcitrance to PD1 and CTLA4 immune checkpoint therapies (ICTs). Here, we sought to systematically characterize the mechanisms underlying de novo ICT resistance and to identify effective therapeutic options for PDAC. We report that agonist 41BB and antagonist LAG3 ICT alone and in combination, increased survival and antitumor immunity, characterized by modulating T cell subsets with antitumor activity, increased T cell clonality and diversification, decreased immunosuppressive myeloid cells and increased antigen presentation/decreased immunosuppressive capability of myeloid cells. Translational analyses confirmed the expression of 41BB and LAG3 in human PDAC. Since single and dual ICTs were not curative, T cell-activating ICTs were combined with a CXCR1/2 inhibitor targeting immunosuppressive myeloid cells. Triple therapy resulted in durable complete responses. Given similar profiles in human PDAC and the availability of these agents for clinical testing, our findings provide a testable hypothesis for this lethal disease.en-USPublisher PolicyPancreatic ductal carcinomaMyeloid cellsPancreatic neoplasmsT-Lymphocyte subsetsArticle